|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
Basic Trial Information
Summary Aim of the study is to establish in a prospective, randomized clinical trial the activity of primary chemotherapy containing high dose-methotrexate, alone or combined with high dose cytarabine, in patients with primary central nervous system lymphoma Eligibility Criteria Inclusion Criteria: 1. Histological or cytological diagnosis of non-Hodgkin's lymphoma. 2. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy. 3. Disease exclusively localized into the central nervous system, cranial nerves or eyes. 4. Untreated patients (patients treated with steroids alone are eligible). 5. At least one measurable lesion. 6. Age 18 - 75 years. 7. ECOG performance status < 3 8. HBsAg-negative and Ab anti-HCV-negative serologic status. 9. No known HIV disease or immunodeficiency. 10. Adequate bone marrow (PLT > 100000 mm3, Hb ≥ 9 g/dl, ANC ≥ 2.000 mm3), renal (creatinine clearance ≥ 60 mL/min), cardiac (VEF ≥ 50%), and hepatic function (total serum bilirubin < 3 mg/dL, AST/ALT and gGT < 2 per upper normal limit value). 11. No previous or concurrent malignancies with the exception of surgically cured cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer and of other cancers without evidence of disease since at least 5 years (patients with a previous lymphoma diagnosis will be excluded). 12. Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. 13. Non-pregnant and non-lactating status for female patients. Adequate contraceptive measures during study participation for sexually active patients of childbearing potential. 14. No concurrent treatment with other experimental drugs. 15. Informed consent signed by the patient before registration Trial Lead Organizations/Sponsors International Extranodal Lymphoma Study Group
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |